ABSTRACT
Research question
Is magnetic-activated cell sorting (MACS) a safe semen sample processing technique
for the newborns and mothers when used for semen processing prior to ICSI cycles?
Design
Retrospective multicentre cohort study involving patients undergoing ICSI cycles with
either donor or their own oocytes from January 2008 to February 2020 divided into
two groups: those who underwent standard semen preparation (reference) and those who
had an added MACS procedure (MACS). 25,356 deliveries were assessed in the case of
cycles using donor oocytes and 19,703 deliveries from cycles using autologous oocytes.
Of those, 20,439 and 15,917 respectively were singleton deliveries. Obstetric and
perinatal outcomes were retrospectively assessed. All means, rates and incidences
were computed per live newborn in each study group.
Results
There were no significant differences between the main obstetric and perinatal morbidities
threatening the mothers’ and newborns’ wellbeing between groups using neither donated
or autologous oocytes. There was a significant increase in the incidence of gestational
anaemia in both subpopulations. However, this incidence was within the estimated prevalence
of gestational anaemia in the general population. There was statistically significant
decrease in preterm and very preterm birth rates in the MACS group in cycles using
donor oocytes.
Conclusions
The use of MACS during semen preparation before ICSI using either donor or the patient's
own oocytes appears to be safe for the mothers’ and newborns’ wellbeing during pregnancy
and birth. Nevertheless, close follow up of these parameters in the future is advised,
mainly concerning anaemia, in order to detect even smaller effect size.
Study funding/competing interest(s)
N/A
KEY WORDS
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Reproductive BioMedicine OnlineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Biography
María Gil Juliá is a predoctoral researcher of the Andrology and Male Infertility group at IVI Foundation. She obtained a MSc in Biotechnology of Human Assisted Reproduction by the Universidad de Valencia in 2020 and a MRes in Biomedical Research by Imperial College London in 2018.
Article info
Publication history
Accepted:
January 27,
2023
Received in revised form:
December 20,
2022
Received:
October 19,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
